A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
Seagen Inc.
Seagen Inc.
Taiho Oncology, Inc.
University of Pittsburgh
Sanofi
City of Hope Medical Center